{"id":"NCT02910063","sponsor":"Amgen","briefTitle":"Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL","officialTitle":"A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-01-23","primaryCompletion":"2020-03-12","completion":"2020-03-12","firstPosted":"2016-09-21","resultsPosted":"2021-01-13","lastUpdate":"2021-01-13"},"enrollment":41,"design":{"allocation":"NA","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["B-Cell Non Hodgkin Lymphoma"],"interventions":[{"type":"DRUG","name":"Blinatumomab","otherNames":["AMG 103","Blincyto"]}],"arms":[{"label":"Blinatumomab","type":"EXPERIMENTAL"}],"summary":"This is a phase 2/3 open label, multicenter trial testing blinatumomab monotherapy for the treatment of subjects with Relapsed/Refractory (R/R) aggressive B-NHL not achieving CMR after 2 cycles of standard platinum-based chemotherapy regimens administered as S1. This study incorporates multiple interim analyses for futility, efficacy, and unblinded sample-size re-estimation. In the phase 3 part of the study, blinatumomab will be compared to Investigator's Choice chemotherapy.\n\nIn March 2019, decision made to not proceed with phase 3.","primaryOutcome":{"measure":"Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR)","timeFrame":"Up to 12 weeks after first dose of blinatumomab","effectByArm":[{"arm":"Phase 2: Blinatumomab","deltaMin":22,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":13},"locations":{"siteCount":31,"countries":["United States","Australia","Belgium","Canada","Italy","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["32546071"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":41},"commonTop":["Headache","Pyrexia","Back pain","Tremor","Oedema peripheral"]}}